Are you over 18 and want to see adult content?
More Annotations
A complete backup of veteransinagriculture.org
Are you over 18 and want to see adult content?
A complete backup of studentclearinghouse.org
Are you over 18 and want to see adult content?
A complete backup of ppgvoiceofcolor.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of velkemoznosti.cz
Are you over 18 and want to see adult content?
A complete backup of charlestonwv.com
Are you over 18 and want to see adult content?
A complete backup of digitaldatatactics.com
Are you over 18 and want to see adult content?
A complete backup of academiainmaculada.com
Are you over 18 and want to see adult content?
A complete backup of nisanreklam.com.tr
Are you over 18 and want to see adult content?
A complete backup of golf-glendale.com
Are you over 18 and want to see adult content?
A complete backup of fitnessfriandises.fr
Are you over 18 and want to see adult content?
Text
PENS AND NEEDLES
Pens. Our innovative injection pens combine patient insight with engineering excellence to make drug delivery as simple as possible. View our broad range of disposable pre-filled pens, durable pens with replaceable insulin cartridges and smart connected pens for diabetes treatment that meets your needs.NOVOPEN® 5
NovoPen ® 5 is the culmination of more than 25 years of NovoPen ® experience. With the additional benefit of an easy-to-use memory function, it builds on the strong design and performance of its predecessor, the popular NovoPen ® 4.NOVOPEN ECHO®
Majken Enggaard is living with type 1 diabetes, Denmark. NovoPen Echo®. As a parent or caregiver, you know how worrying it can be to trust your child's diabetes management, especially when they're not at home. The NovoPen Echo® is a durable pen designed to help your child manage his/her insulin dosing more confidently.NOVOPEN® 6
NovoPen ® 6 & NovoPen Echo ® Plus are new, smart insulin pens that automatically record insulin dosing information about each injection. So you don’t have to. NovoPen ® 6 or NovoPen Echo ® Plus must be prescribed by your healthcare provider. NovoPen ® 6 & NovoPen Echo ® Plus are intended for patients who have been prescribed Novo Nordisk insulin in cartridge. STRATEGIC ASPIRATIONS FOR 2025 Strengthen Diabetes leadership - aim at global value market share of more than 1/3; Strengthen Obesity leadership and double current sales (based on reported sales in 2019) CLIMATE-RELATED FINANCIAL DISCLOSURES The industry-led Task Force on Climate-related Financial Disclosures (TCFD) establishes recommendations for disclosing clear, comparable and consistent information about the risks and opportunities presented by climate change. It is expected to help companies better demonstrate responsibility and foresight in how they consider climate changeMARCUS SCHINDLER
Former Positions. Prior to joining Novo Nordisk Dr Schindler was Vice President, head of Cardiovascular and Metabolic Diseases innovative Medicines (CVMD iMed) at AstraZeneca, Sweden. From 2009-2012 he was head of Research at (OSI) Prosidion, Oxford, UK. From 2000-2008 he worked in various leadership roles at Boehringer Ingelheim, Germanyafter
NOVO NORDISK KALUNDBORG Novo Nordisk Kalundborg. Novo Nordisk Kalundborg is growing these years. Since the turn of the millennium alone, Novo Nordisk has invested more than 16 billion DKK in Kalundborg. Today, our 3,000 employees produce half of the world’s insulin and a number of biopharmaceutical products. Furthermore, our finished product sectionsassemble and
MARTIN MACKAY
Positions and management duties. Co-founder, chair of the Board, CEO and holder of an executive leadership role overseeing all research and non-research functions, Rallybio LLC. Senior advisor to New Leaf Venture Partners, LLC. Member of the board of 5:01 Acquisition Corporation. Member of the board and chair of the Science andTechnology
NOVO NORDISK, DRIVING CHANGE TO DEFEAT DIABETESCAREERSABOUT NOVO NORDISKCONTACT USINVESTORSGLOBAL OFFICESSEARCH Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.PENS AND NEEDLES
Pens. Our innovative injection pens combine patient insight with engineering excellence to make drug delivery as simple as possible. View our broad range of disposable pre-filled pens, durable pens with replaceable insulin cartridges and smart connected pens for diabetes treatment that meets your needs.NOVOPEN® 5
NovoPen ® 5 is the culmination of more than 25 years of NovoPen ® experience. With the additional benefit of an easy-to-use memory function, it builds on the strong design and performance of its predecessor, the popular NovoPen ® 4.NOVOPEN ECHO®
Majken Enggaard is living with type 1 diabetes, Denmark. NovoPen Echo®. As a parent or caregiver, you know how worrying it can be to trust your child's diabetes management, especially when they're not at home. The NovoPen Echo® is a durable pen designed to help your child manage his/her insulin dosing more confidently. LOCATIONS - NOVO NORDISK Novo Nordisk A/S Novo Allé 1 2880 Bagsværd Denmark +45-4444-8888CVR-no. 24256790
THE NOVO NORDISK FOUNDATION The Novo Nordisk Foundation may in connection with a capital increase in Novo Nordisk or a merger of Novo Nordisk with other companies waive its controlling interest in Novo Nordisk if it is necessary to uphold and develop the commercial and research activities of Novo Nordisk as an internationally competitive business.OPEN INNOVATION
Novo Nordisk A/S Novo Allé 1 2880 Bagsværd Denmark +45-4444-8888CVR-no. 24256790
NORDIFLEX®
NordiFlex® - with Novo Nordisk needles. NordiFlex® can be used with Novo Nordisk ultra-thin, ultra-short needles – including NovoTwist®, NovoFine®, and NovoFine® Autocover® – designed for ease of use and less pain and anxiety during injection. Please ask your doctor for more information.RESEARCH PARTNERING
Research partnering. We are interested in novel targets, innovative compounds and technologies that address unmet medical needs, and have the potential to be disease modifying, for people living with a serious chronic disease. Partnerships based on long-term commitment and mutual interest, and open innovation platforms that shareknowledge and
NOVOPEN® 4
3. Easy-to-set and easy-to-read dose display. 4. Easy-to-use dial. Easily correct a dose by simply turning the dial the other way. Clicks when dialling up and down. Dial will not select more units than what is left in the cartridge. 5. Robust design that is built to last up to5 years.
NOVO NORDISK KALUNDBORG Novo Nordisk Kalundborg. Novo Nordisk Kalundborg is growing these years. Since the turn of the millennium alone, Novo Nordisk has invested more than 16 billion DKK in Kalundborg. Today, our 3,000 employees produce half of the world’s insulin and a number of biopharmaceutical products. Furthermore, our finished product sectionsassemble and
OBESITY - NOVO NORDISK Obesity can seem straightforward to explain. If a person consumes more calories than they need, they gain weight. But the real explanation is not that simple. And it is about more than weight. Obesity is a complex chronic disease, and losing weight is not just a question of eating less and moving more. In fact, obesity can be influenced by NOVO NORDISK RESPONSIBLE SOURCING STANDARDS Anti-corruption Human Rights Environment Health & Safety Management 3 Novo Nordisk Responsible Sourcing Standards 3.0, 2019 Freely chosen employment • When a written employment contract or letter JOB AD - NOVONORDISK.COM Novo Nordisk A/S Novo Allé 1 2880 Bagsværd Denmark +45-4444-8888CVR-no. 24256790
NOVO NORDISK, DRIVING CHANGE TO DEFEAT DIABETESCAREERSABOUT NOVO NORDISKCONTACT USINVESTORSGLOBAL OFFICESSEARCH Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases. LOCATIONS - NOVO NORDISK Novo Nordisk A/S Novo Allé 1 2880 Bagsværd Denmark +45-4444-8888CVR-no. 24256790
PENS AND NEEDLES
Pens. Our innovative injection pens combine patient insight with engineering excellence to make drug delivery as simple as possible. View our broad range of disposable pre-filled pens, durable pens with replaceable insulin cartridges and smart connected pens for diabetes treatment that meets your needs.NOVOPEN® 6
NovoPen ® 6 & NovoPen Echo ® Plus are new, smart insulin pens that automatically record insulin dosing information about each injection. So you don’t have to. NovoPen ® 6 or NovoPen Echo ® Plus must be prescribed by your healthcare provider. NovoPen ® 6 & NovoPen Echo ® Plus are intended for patients who have been prescribed Novo Nordisk insulin in cartridge. CAREERS - NOVO NORDISK Novo Nordisk A/S Novo Allé 1 2880 Bagsværd Denmark +45-4444-8888CVR-no. 24256790
NOVOPEN® 5
NovoPen ® 5 is the culmination of more than 25 years of NovoPen ® experience. With the additional benefit of an easy-to-use memory function, it builds on the strong design and performance of its predecessor, the popular NovoPen ® 4.NORDIFLEX®
NordiFlex® - with Novo Nordisk needles. NordiFlex® can be used with Novo Nordisk ultra-thin, ultra-short needles – including NovoTwist®, NovoFine®, and NovoFine® Autocover® – designed for ease of use and less pain and anxiety during injection. Please ask your doctor for more information.NOVOPEN ECHO®
Majken Enggaard is living with type 1 diabetes, Denmark. NovoPen Echo®. As a parent or caregiver, you know how worrying it can be to trust your child's diabetes management, especially when they're not at home. The NovoPen Echo® is a durable pen designed to help your child manage his/her insulin dosing more confidently. OBESITY - NOVO NORDISK Obesity can seem straightforward to explain. If a person consumes more calories than they need, they gain weight. But the real explanation is not that simple. And it is about more than weight. Obesity is a complex chronic disease, and losing weight is not just a question of eating less and moving more. In fact, obesity can be influenced byMARCUS SCHINDLER
Former Positions. Prior to joining Novo Nordisk Dr Schindler was Vice President, head of Cardiovascular and Metabolic Diseases innovative Medicines (CVMD iMed) at AstraZeneca, Sweden. From 2009-2012 he was head of Research at (OSI) Prosidion, Oxford, UK. From 2000-2008 he worked in various leadership roles at Boehringer Ingelheim, Germanyafter
NOVO NORDISK, DRIVING CHANGE TO DEFEAT DIABETESCAREERSABOUT NOVO NORDISKCONTACT USINVESTORSGLOBAL OFFICESSEARCH Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases. LOCATIONS - NOVO NORDISK Novo Nordisk A/S Novo Allé 1 2880 Bagsværd Denmark +45-4444-8888CVR-no. 24256790
PENS AND NEEDLES
Pens. Our innovative injection pens combine patient insight with engineering excellence to make drug delivery as simple as possible. View our broad range of disposable pre-filled pens, durable pens with replaceable insulin cartridges and smart connected pens for diabetes treatment that meets your needs.NOVOPEN® 6
NovoPen ® 6 & NovoPen Echo ® Plus are new, smart insulin pens that automatically record insulin dosing information about each injection. So you don’t have to. NovoPen ® 6 or NovoPen Echo ® Plus must be prescribed by your healthcare provider. NovoPen ® 6 & NovoPen Echo ® Plus are intended for patients who have been prescribed Novo Nordisk insulin in cartridge. CAREERS - NOVO NORDISK Novo Nordisk A/S Novo Allé 1 2880 Bagsværd Denmark +45-4444-8888CVR-no. 24256790
NOVOPEN® 5
NovoPen ® 5 is the culmination of more than 25 years of NovoPen ® experience. With the additional benefit of an easy-to-use memory function, it builds on the strong design and performance of its predecessor, the popular NovoPen ® 4.NORDIFLEX®
NordiFlex® - with Novo Nordisk needles. NordiFlex® can be used with Novo Nordisk ultra-thin, ultra-short needles – including NovoTwist®, NovoFine®, and NovoFine® Autocover® – designed for ease of use and less pain and anxiety during injection. Please ask your doctor for more information.NOVOPEN ECHO®
Majken Enggaard is living with type 1 diabetes, Denmark. NovoPen Echo®. As a parent or caregiver, you know how worrying it can be to trust your child's diabetes management, especially when they're not at home. The NovoPen Echo® is a durable pen designed to help your child manage his/her insulin dosing more confidently. OBESITY - NOVO NORDISK Obesity can seem straightforward to explain. If a person consumes more calories than they need, they gain weight. But the real explanation is not that simple. And it is about more than weight. Obesity is a complex chronic disease, and losing weight is not just a question of eating less and moving more. In fact, obesity can be influenced byMARCUS SCHINDLER
Former Positions. Prior to joining Novo Nordisk Dr Schindler was Vice President, head of Cardiovascular and Metabolic Diseases innovative Medicines (CVMD iMed) at AstraZeneca, Sweden. From 2009-2012 he was head of Research at (OSI) Prosidion, Oxford, UK. From 2000-2008 he worked in various leadership roles at Boehringer Ingelheim, Germanyafter
LOCATIONS - NOVO NORDISK Novo Nordisk A/S Novo Allé 1 2880 Bagsværd Denmark +45-4444-8888CVR-no. 24256790
INVESTORS - NOVO NORDISK Novo Nordisk A/S Novo Allé 1 2880 Bagsværd Denmark +45-4444-8888CVR-no. 24256790
OPEN INNOVATION
Novo Nordisk A/S Novo Allé 1 2880 Bagsværd Denmark +45-4444-8888CVR-no. 24256790
NEWS DETAILS
Novo Nordisk to acquire Corvidia Therapeutics and expand presence in cardiovascular disease. Bagsværd, Denmark, 11 June 2020 – Novo Nordisk A/S today announced that it has entered into a definitive agreement to acquire Corvidia Therapeutics Inc., a privately held, clinical stage company focused on the research and development of transformative therapies for cardio-renal diseases. THE NOVO NORDISK FOUNDATION The Novo Nordisk Foundation may in connection with a capital increase in Novo Nordisk or a merger of Novo Nordisk with other companies waive its controlling interest in Novo Nordisk if it is necessary to uphold and develop the commercial and research activities of Novo Nordisk as an internationally competitive business. INSTRUCTIONS FOR USE Instructions for use: our pens and needles. Since providing the world’s first injection system more than 90 years ago, we have been committed to making drug delivery as simple and convenient as possible. On this page you will find the instructions for use (IFU) for our durable pens and devices in your language.NOVOPEN® 4
3. Easy-to-set and easy-to-read dose display. 4. Easy-to-use dial. Easily correct a dose by simply turning the dial the other way. Clicks when dialling up and down. Dial will not select more units than what is left in the cartridge. 5. Robust design that is built to last up to5 years.
NOVO NORDISK KALUNDBORG Novo Nordisk Kalundborg. Novo Nordisk Kalundborg is growing these years. Since the turn of the millennium alone, Novo Nordisk has invested more than 16 billion DKK in Kalundborg. Today, our 3,000 employees produce half of the world’s insulin and a number of biopharmaceutical products. Furthermore, our finished product sectionsassemble and
BUSINESS INNOVATION GARAGE We believe that building solid collaborations with digital start-ups will help us to adapt quicker to industry changes. Our collaboration models are designed to build a bridge between start-ups and our innovation garage internal teams. LARS FRUERGAARD JØRGENSEN Career at Novo Nordisk. Mr Jørgensen joined Novo Nordisk in 1991 as an economist in Health Care, Economy & Planning and has over the years completed overseas postings in the Netherlands, the US and Japan. In 2004 he was appointed senior vice president for IT & Corporate Development. In January 2013 he was appointed executive vice presidentand
NOVO NORDISK, DRIVING CHANGE TO DEFEAT DIABETESCAREERSABOUT NOVO NORDISKCONTACT USINVESTORSGLOBAL OFFICESSEARCH Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.PENS AND NEEDLES
Pens. Our innovative injection pens combine patient insight with engineering excellence to make drug delivery as simple as possible. View our broad range of disposable pre-filled pens, durable pens with replaceable insulin cartridges and smart connected pens for diabetes treatment that meets your needs.NOVOPEN® 5
NovoPen ® 5 is the culmination of more than 25 years of NovoPen ® experience. With the additional benefit of an easy-to-use memory function, it builds on the strong design and performance of its predecessor, the popular NovoPen ® 4.NOVOPEN ECHO®
Majken Enggaard is living with type 1 diabetes, Denmark. NovoPen Echo®. As a parent or caregiver, you know how worrying it can be to trust your child's diabetes management, especially when they're not at home. The NovoPen Echo® is a durable pen designed to help your child manage his/her insulin dosing more confidently. THE NOVO NORDISK FOUNDATION The Novo Nordisk Foundation may in connection with a capital increase in Novo Nordisk or a merger of Novo Nordisk with other companies waive its controlling interest in Novo Nordisk if it is necessary to uphold and develop the commercial and research activities of Novo Nordisk as an internationally competitive business. STRATEGIC ASPIRATIONS FOR 2025 Strengthen Diabetes leadership - aim at global value market share of more than 1/3; Strengthen Obesity leadership and double current sales (based on reported sales in 2019) CLIMATE-RELATED FINANCIAL DISCLOSURES The industry-led Task Force on Climate-related Financial Disclosures (TCFD) establishes recommendations for disclosing clear, comparable and consistent information about the risks and opportunities presented by climate change. It is expected to help companies better demonstrate responsibility and foresight in how they consider climate change OBESITY - NOVO NORDISK Obesity can seem straightforward to explain. If a person consumes more calories than they need, they gain weight. But the real explanation is not that simple. And it is about more than weight. Obesity is a complex chronic disease, and losing weight is not just a question of eating less and moving more. In fact, obesity can be influenced byMARCUS SCHINDLER
Former Positions. Prior to joining Novo Nordisk Dr Schindler was Vice President, head of Cardiovascular and Metabolic Diseases innovative Medicines (CVMD iMed) at AstraZeneca, Sweden. From 2009-2012 he was head of Research at (OSI) Prosidion, Oxford, UK. From 2000-2008 he worked in various leadership roles at Boehringer Ingelheim, Germanyafter
MARTIN MACKAY
Positions and management duties. Co-founder, chair of the Board, CEO and holder of an executive leadership role overseeing all research and non-research functions, Rallybio LLC. Senior advisor to New Leaf Venture Partners, LLC. Member of the board of 5:01 Acquisition Corporation. Member of the board and chair of the Science andTechnology
NOVO NORDISK, DRIVING CHANGE TO DEFEAT DIABETESCAREERSABOUT NOVO NORDISKCONTACT USINVESTORSGLOBAL OFFICESSEARCH Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.PENS AND NEEDLES
Pens. Our innovative injection pens combine patient insight with engineering excellence to make drug delivery as simple as possible. View our broad range of disposable pre-filled pens, durable pens with replaceable insulin cartridges and smart connected pens for diabetes treatment that meets your needs.NOVOPEN® 5
NovoPen ® 5 is the culmination of more than 25 years of NovoPen ® experience. With the additional benefit of an easy-to-use memory function, it builds on the strong design and performance of its predecessor, the popular NovoPen ® 4.NOVOPEN ECHO®
Majken Enggaard is living with type 1 diabetes, Denmark. NovoPen Echo®. As a parent or caregiver, you know how worrying it can be to trust your child's diabetes management, especially when they're not at home. The NovoPen Echo® is a durable pen designed to help your child manage his/her insulin dosing more confidently. THE NOVO NORDISK FOUNDATION The Novo Nordisk Foundation may in connection with a capital increase in Novo Nordisk or a merger of Novo Nordisk with other companies waive its controlling interest in Novo Nordisk if it is necessary to uphold and develop the commercial and research activities of Novo Nordisk as an internationally competitive business. STRATEGIC ASPIRATIONS FOR 2025 Strengthen Diabetes leadership - aim at global value market share of more than 1/3; Strengthen Obesity leadership and double current sales (based on reported sales in 2019) CLIMATE-RELATED FINANCIAL DISCLOSURES The industry-led Task Force on Climate-related Financial Disclosures (TCFD) establishes recommendations for disclosing clear, comparable and consistent information about the risks and opportunities presented by climate change. It is expected to help companies better demonstrate responsibility and foresight in how they consider climate change OBESITY - NOVO NORDISK Obesity can seem straightforward to explain. If a person consumes more calories than they need, they gain weight. But the real explanation is not that simple. And it is about more than weight. Obesity is a complex chronic disease, and losing weight is not just a question of eating less and moving more. In fact, obesity can be influenced byMARCUS SCHINDLER
Former Positions. Prior to joining Novo Nordisk Dr Schindler was Vice President, head of Cardiovascular and Metabolic Diseases innovative Medicines (CVMD iMed) at AstraZeneca, Sweden. From 2009-2012 he was head of Research at (OSI) Prosidion, Oxford, UK. From 2000-2008 he worked in various leadership roles at Boehringer Ingelheim, Germanyafter
MARTIN MACKAY
Positions and management duties. Co-founder, chair of the Board, CEO and holder of an executive leadership role overseeing all research and non-research functions, Rallybio LLC. Senior advisor to New Leaf Venture Partners, LLC. Member of the board of 5:01 Acquisition Corporation. Member of the board and chair of the Science andTechnology
LOCATIONS - NOVO NORDISK Novo Nordisk A/S Novo Allé 1 2880 Bagsværd Denmark +45-4444-8888CVR-no. 24256790
OPEN INNOVATION
Novo Nordisk A/S Novo Allé 1 2880 Bagsværd Denmark +45-4444-8888CVR-no. 24256790
NORDIFLEX®
NordiFlex® - with Novo Nordisk needles. NordiFlex® can be used with Novo Nordisk ultra-thin, ultra-short needles – including NovoTwist®, NovoFine®, and NovoFine® Autocover® – designed for ease of use and less pain and anxiety during injection. Please ask your doctor for more information.NOVOPEN® 6
NovoPen ® 6 & NovoPen Echo ® Plus are new, smart insulin pens that automatically record insulin dosing information about each injection. So you don’t have to. NovoPen ® 6 or NovoPen Echo ® Plus must be prescribed by your healthcare provider. NovoPen ® 6 & NovoPen Echo ® Plus are intended for patients who have been prescribed Novo Nordisk insulin in cartridge.NEWS DETAILS
Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes. Bagsværd, Denmark, 20 January 2021 – Novo Nordisk today announced the submission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation for Ozempic ®, a once-weekly glucagon-like peptide-1 (GLP-1NOVOPEN® 4
3. Easy-to-set and easy-to-read dose display. 4. Easy-to-use dial. Easily correct a dose by simply turning the dial the other way. Clicks when dialling up and down. Dial will not select more units than what is left in the cartridge. 5. Robust design that is built to last up to5 years.
FIND A JOB - NOVONORDISK.COM To access your profile outside of the application process you will need to select a position on the website and click Apply now.. Once you click Apply now you will be routed to the position page where you can select View Profile from the top menu bar, sign in and open the Jobs Applied accordion. After you sign in you will be able to view the position(s) to which you have applied, view your NOVO NORDISK KALUNDBORG Novo Nordisk Kalundborg. Novo Nordisk Kalundborg is growing these years. Since the turn of the millennium alone, Novo Nordisk has invested more than 16 billion DKK in Kalundborg. Today, our 3,000 employees produce half of the world’s insulin and a number of biopharmaceutical products. Furthermore, our finished product sectionsassemble and
CAREERS AT NOVO NORDISK Dhaka, Dhaka, BD Clinical Development and Medical: 06-May-2021 Multi Channel Engagement ManagerSIGN IN
Sign in with your organizational account. User Account. Password __Information__Functionality__Statistics__MarketingCOOKIES
INFORMATION ABOUT COOKIES A cookie is a small text file, which is placed on your computer or other device. It makes it possible for us to recognise your computer and gather information about which pages and functions are visited with your computer. Cookies contain only anonymous information. Cookies are used by most websites and are in many cases essential for the website to work properly. COOKIES ON THIS WEBSITE We use cookies on this website for various purposes related to functionality, web analysis and marketing. However, most cookies we use to gather statistics about your visit. This information we can use to improve the user experience on our website. You can read more about the cookies we use under the three tabs. The cookies are divided into categories and you will find information about name, expiration, purpose and company. HOW TO DISABLE COOKIES IN YOUR BROWSER If you want to block the use of cookies you must change the permissions in your browser setting. If you block cookies in your browser, your device will not be tracked when you visit our website. However, please note that by declining cookies some website functionalities may not work correctly. WHY DO WE INFORM ABOUT COOKIES? We inform about cookies because we want to be transparent in the way we communicate with our stakeholders. EU has also made a privacy directive which you can read more about here: General Data Protection Regulation (EU) 2016/679 ("GDPR") Powered by Siteimprove__ Close
__
You accept the use of cookies by continuing to browse the site or closing this banner. About Cookies__ Close__
Cookies
__
__ __
Back
* Patients
Patients
Diabetes
* Diabetes
* Type 1
* Type 2
* Gestational diabetes * Pens, needles and injection supportObesity
* Obesity
* Understanding obesity* Treating obesity
* Living with obesityHaemophilia
Growth disorders
Hormone replacement therapy Disease experience expert panel (DEEP) A partnership that benefits patientsClinical trials
What is a clinical trial and how to participate. * Research & Development Research & Development Science & innovation * Science & innovation * Our scientific approach * Stem cell research * R&D facts & figures * Global R&D centres* Publications
Our therapy areas
* Our therapy areas
* Type 1 diabetes
* Type 2 diabetes
* Obesity
* Atherosclerosis
* NASH
* Haemophilia
* Growth disorders
Partner with us
* Partner with us
* Partnering opportunities* Events & meetings
* Contact us
Future science
Look at our future sciencePipeline
Review our clinical pipelineClinical trials
What is a clinical trial and how to participateBioethics
* Bioethics
* Animal ethics
* Clinical trial ethics * Human biosample ethics* Stem cell ethics
* Gene technology ethics * Sustainable business Sustainable business A sustainable company We believe that a healthy environment, society and economy are fundamental to long-term business success, and we will play our part, also on the long-term. Access and affordability in diabetes * Access and affordability in diabetes * Our access to insulin commitment * Medicines affordability in the US * Programmes and partnerships * World Diabetes Foundation * Novo Nordisk Haemophilia Foundation Zero environmental impact Preventing type 2 diabetes Transparency & reporting* Human rights
* Integrated reporting * The Sustainable Development Goals * Principles, positions and policies Frequently asked questions Find answers to some of the more frequently asked questions on sustainability and responsible business practices.* Careers
Careers
Join us
* Available Jobs
* Email Job Agent
* Working at Novo Nordisk * Employee Perspectives* Moving to Denmark
* Meet Us - Event CalendarProfessionals
* Research & Development* Manufacturing
* Corporate Functions * Finance, Investor Relations, and Procurement* IT
Career programmes
* PhD and PostDocs
* Pharmaceutical Medicine Programme (PMP) Graduates, students and trainees* Graduates
* Students
* Trainees - Elev
* About Novo Nordisk * Media
* Products
* Investors
* Partnering
* Contact us
*
Novo Nordisk Worldwide*
WE DON'T WAIT FOR CHANGE, WE DRIVE CHANGE Together we make it happen. Together we're life changing. Join us for a life-changing career .OUR RESEARCH AREAS
Type 1 diabetes
Type 2 diabetes
Obesity
Atherosclerosis
NASH
Haemophilia
Growth disorders
NEWS
bluebird bio and Novo Nordisk enter into research agreement to develop in vivo g...09 Oct 2019
Novo Nordisk and Noom to partner around digital health solutions tohelp people ...
01 Oct 2019
Media
339 We offer 339 job opportunities Denmark (126)China (31)Argentina (1)Australia (1)Austria (2)Bangladesh (1)Belgium (6)Brazil (3)Canada (31)Chile (1)Egypt (1)France (16)Germany (4)India (56)Ireland (2)Israel (2)Italy (2)Kazakhstan (3)Kenya (1)Kuwait (1)Malaysia (8)Mexico (7)Netherlands (1)Poland (3)Russia (5)South Africa (2)Spain (1)Sweden (1)Thailand (1)Tunisia (1)Turkey (1)Ukraine (12)United Arab Emirates (1)United Kingdom (1)Vietnam (3)Countries (All)
* Select/Deselect All* Denmark (126)
* China (31)
* Argentina (1)
* Australia (1)
* Austria (2)
* Bangladesh (1)
* Belgium (6)
* Brazil (3)
* Canada (31)
* Chile (1)
* Egypt (1)
* France (16)
* Germany (4)
* India (56)
* Ireland (2)
* Israel (2)
* Italy (2)
* Kazakhstan (3)
* Kenya (1)
* Kuwait (1)
* Malaysia (8)
* Mexico (7)
* Netherlands (1)
* Poland (3)
* Russia (5)
* South Africa (2)
* Spain (1)
* Sweden (1)
* Thailand (1)
* Tunisia (1)
* Turkey (1)
* Ukraine (12)
* United Arab Emirates (1) * United Kingdom (1)* Vietnam (3)
Clinical Development & Medical (48)Engineering (9)Finance (5)General Management & Administration (13)Human Resource Management (7)IT Services (40)Legal, Compliance & Audit (7)Manufacturing (45)Marketing & Market Access (19)Project Management (5)Quality (20)Research (26)Supply Chain & Procurement (7)Communication & Corporate Affairs (3)Sales (79)Regulatory (6)All Selected
* Select All
* Clinical Development & Medical (48)* Engineering (9)
* Finance (5)
* General Management & Administration (13) * Human Resource Management (7)* IT Services (40)
* Legal, Compliance & Audit (7) * Manufacturing (45) * Marketing & Market Access (19) * Project Management (5)* Quality (20)
* Research (26)
* Supply Chain & Procurement (7) * Communication & Corporate Affairs (3)* Sales (79)
* Regulatory (6)
Search
For jobs in the United States, please visit our US career site.
------------------------- TURNING SCIENTIFIC IDEAS INTO MEDICINES From formulating protein molecules in a tablet to stem cell research, our scientists are always striving for the next breakthrough. Read more about our work in the lab ------------------------- MAKING OUR MEDICINES ACCESSIBLE AND AFFORDABLE For many people with diabetes, insulin is an essential, life-saving medicine. It’s our ambition that everyone who needs insulin has access to it at prices they can afford. Read more about our access and affordability programmes ------------------------- PREVENTING THE RISE OF TYPE 2 DIABETES The huge rise in type 2 diabetes around the world is catastrophic. Uncontrolled, this rise is not sustainable for anyone – people, health systems, businesses or economies. Bending the curve on diabetes is therefore crucial to all of us. Read about our efforts to prevent type 2 diabetes*
*
*
*
*
*
Overview
WHO WE ARE
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronicdiseases.
Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries, and markets its products in more than 170countries.
NOVO NORDISK WEBSITES * Novo Nordisk in the USA * Novo Nordisk in DenmarkOr choose:
Affiliate sites Argentina Australia Austria Belgium Brazil Bulgaria Canada Chile China Colombia Croatia Czech Republic Denmark Estonia Finland France Germany Greece Hong Kong Hungary India Ireland Israel Italy Japan Korea (Republic) Latvia Lithuania Mexico Moldova Netherlands New Zealand Norway Pakistan Poland Portugal Russia Saudi Arabia Serbia Slovakia Slovenia South Africa Spain Sweden Switzerland Taiwan Tunisia Turkey Ukraine United Arab Emirates United Kingdom USAVenezuela
Affiliate sites
* Affiliate sites
* Argentina
* Australia
* Austria
* Belgium
* Brazil
* Bulgaria
* Canada
* Chile
* China
* Colombia
* Croatia
* Czech Republic
* Denmark
* Estonia
* Finland
* France
* Germany
* Greece
* Hong Kong
* Hungary
* India
* Ireland
* Israel
* Italy
* Japan
* Korea (Republic)
* Latvia
* Lithuania
* Mexico
* Moldova
* Netherlands
* New Zealand
* Norway
* Pakistan
* Poland
* Portugal
* Russia
* Saudi Arabia
* Serbia
* Slovakia
* Slovenia
* South Africa
* Spain
* Sweden
* Switzerland
* Taiwan
* Tunisia
* Turkey
* Ukraine
* United Arab Emirates* United Kingdom
* USA
* Venezuela
Other sites Cities Changing Diabetes Clinical Trials Novo Holdings A/S Novo Nordisk Foundation Novo Nordisk Haemophilia Foundation Novo Nordisk Pharmatech A/S World Diabetes FoundationOther sites
* Other sites
* Cities Changing Diabetes* Clinical Trials
* Novo Holdings A/S
* Novo Nordisk Foundation * Novo Nordisk Haemophilia Foundation * Novo Nordisk Pharmatech A/S * World Diabetes Foundation NOVO NORDISK WORLDWIDE Addresses and global contacts IMPORTANT SAFETY INFORMATION ABOUT COLOUR CHANGE FOR FIASP® FLEXTOUCH® AND FIASP® PENFILL® Read more about the issue SHAREHOLDER INFORMATIONShare Info
ANNUAL REPORTING
Annual Report 2018
CONTACT QUICK LINKS
* Contact customer servicesin your country
* Report a side effect * Report product complaints * Report falsified products * Report a concern to the Compliance Hotline* Media contact
© 2019 Novo Nordisk A/S Disclaimer/PrivacySitemap Contact us
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0